BNC105

DB06313InvestigationalSmall molecule

Investigated for use/treatment in cancer/tumors (unspecified).

Mechanism: BNC105 is a Vascular Targeting Agent (VDA) anticancer drug. VDAs are disrupt the blood vessels which nourish tumours. BNC105 occludes blood vessels which cuts off oxygen and nutrient supply to the tumor cells, and thus can be applied to a wide range of cancerous tumors. It has a dual mode of action where it cuts off blood supply to the tumor and may have a direct toxic effect on cancer cells. Pharmacokinetic studies have been favorable, showing enhanced specificity and a long half life at the tumor site.
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
Formula / weight: C₂₀H₂₁O₁₀P · 452.352 g/mol (avg)
Code names: BNC105 · BNC-105P FREE ACID

Resolves to

Compound

Structure

InChIKeyMYDHDVLPMRNDAZ-UHFFFAOYSA-NSMILESCOC1=CC(=CC(OC)=C1OC)C(=O)C1=C(C)OC2=C1C=CC(OC)=C2OP(O)(O)=O

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of BNC105, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.